Calypso Biotech

Calypso Biotech is the third spin-off company from the EPP Fund. The company is developing antibody therapeutics against niche gastro-intestinal immune disorders, such as refractory celiac disease and Crohn`s Disease. Calypso Biotech is based in Geneva, Switzerland.

http://www.calypsobiotech.com

Latest News Entry
2020/11/16
Calypso Biotech announces successful dosing of first Phase 1 cohort with anti-Interleukin-15 (IL-15) monoclonal antibody CALY-002 for the treatment of Autoimmune Diseases

Dose-escalation study to evaluate safety, biological and early clinical effect of CALY-002 in healthy volunteers and patients with Celiac Disease and Eosinophilic Esophagitis

2017/03/29
Calypso Biotech licenses CALY-001 best-in-class anti-MMP-9 antibody to EA Pharma

Calypso Biotech SA announced today that it has entered a global licensing and collaboration agreement with EA Pharma Co., Ltd. to develop CALY-001, a best-in-class anti-MMP-9 fully human monoclonal antibody.

all portfolio news